11.92 USD
▲+0.71+0.08%
盘后 11.87 -0.30%
2026-08-03
市值
$1.00B
市盈率
—
EPS
-3.38
股息率
—
52 周区间
1.50 – 12.60
成交量
6.09M
Beta
0.97
目标价
11.50
52W 低 1.5052W 高 12.60
价格走势
公司简介
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer in the United States and the United Kingdom. The company’s proprietary oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF for a range of solid tumors. The company is also developing RP2 that expresses an an...